HARNESSING DC SUBSETS FOR IMPROVED MUCOSAL IMMUNITY

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 这是一项比较疫苗研究，以测试哪种靶向DC的载体可以引发针对流感感染的最有效的保护性免疫。抗体介导的免疫是预防流感感染的重要免疫手段。为了评价i.d.给药的DC靶向疫苗的效力，我们使用了一种流行的疫苗，流感疫苗，作为阳性对照。虽然本研究的主要目的是测试HA 1特异性体液应答，但我们也将测试激发有效体液免疫所必需的HA 1特异性细胞应答的幅度和谱。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This is a comparative vaccine study to test which DC-targeting vehicle can elicit the most potent protective immunity against influenza infection. Antibody-mediated immunity is an important immune arm for the prevention of influenza infection. To evaluate the potency of DC-targeting vaccines administered i.d., we employ a current vaccine, Fluzone, as a positive control. Although the main objective of this study is to test HA1-specific humoral responses, we will also test the magnitude and spectrum of HA1-specific cellular responses that are necessary for eliciting potent humoral immunity.